Edesa Biotech Reports Q2 Net Loss of $4.2M, Prepares Midyear Phase 2 Trial
EDSA•Edesa Biotech’s Q2 operating expenses rose $2.7m to $4.3m, driving a net loss of $4.2m, or $0.49 per share. The company affirmed midyear Phase 2 EB06 vitiligo trial activations and reported Phase 3 paridiprubart data showing consistent benefits across severity subgroups.
1. Clinical Pipeline Progress
Edesa continued preparations for its Phase 2 EB06 trial by contracting a clinical research organization, initiating site and investigator outreach, and reaffirming midyear activations and patient recruitment. The company also released additional Phase 3 paridiprubart data demonstrating consistent treatment benefits across disease severities and among patients with acute kidney injury, pneumonia and sepsis.
2. Financial Results
Total operating expenses for the quarter ended March 31 rose by $2.7 million to $4.3 million, driven by a $2.3 million increase in research and development to $2.8 million and a $0.3 million rise in general and administrative costs to $1.5 million. Edesa reported a net loss of $4.2 million, or $0.49 per share, compared to a net loss of $1.6 million, or $0.30 per share, in the same period last year.
3. Liquidity and Outlook
As of March 31, Edesa held $10.0 million in cash and cash equivalents and reported working capital of $8.2 million. Management expects operating expenses to remain elevated as clinical activities accelerate and plans to engage investors and partners at upcoming industry conferences.
